Viral Therapy in Treating Patients With Relapsed or Refractory Multiple Myeloma

Inclusion Criteria: * Patient must have relapsed or refractory myeloma that fits or did fit IMWG diagnostic criteria for symptomatic myeloma (although new or worsening end-organ damage is not required to be eligible) as defined below: * Presence of ≥ 10% clonal bone marrow plasma cells * Presence of serum and/or urinary measurable monoclonal protein or light chains * Evidence of any end-organ damage criteria listed below \[at any time\] attributed to the patient's myeloma: * Hypercalcemia: Serum calcium \> 11.5 mg/dL * Renal insufficiency: Serum creatinine \> 2 mg/dL * Anemia \> 2 g/dL below the lower limit of normal or a hemoglobin value \< 10 g/dL * Bone lesions: Lytic lesions, severe osteopenia, or pathologic fractures * Subject must have measurable disease defined as any of the following: * Serum monoclonal protein \> 500 mg/dL by protein electrophoresis * \> 200 mg of monoclonal protein in the urine on 24-hour electrophoresis * Serum immunoglobulin free light chain ≥ 100 mg/L AND abnormal serum immunoglobulin kappa to lambda free light chain ratio * Patients must have received at least one prior antineoplastic therapy and must have progressed * No standard therapy is available or patient declines such options * Prior autologous and/or allogeneic transplant is permitted although transplant must have occurred greater than 90 days prior to registration * Adverse events from prior therapy must have recovered to no greater than grade 1 with the…